PROX1 and acute myeloid leukemia: To explore the clinical implications of the dysregulated lncRNAs, first, we analyzed the gene expression profiling of AML collected at diagnosis, and compared the expression of FTO, LN892, LN989, PROX1-AS1, and SENCR among different response groups.